Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
DURLAZA
Overview
What is DURLAZA?
DURLAZA Capsules contain aspirin, which is a platelet aggregation inhibitor, for oral administration. Chemically, aspirin is acetylsalicylic acid. It has the following structural formula:
Aspirin is white or almost white crystalline powder or colorless crystals consisting of cubical and squared crystals. It is slightly soluble in water, and soluble in ethanol. When exposed to moisture, aspirin hydrolyzes into salicylic and acetic acids, and gives off a vinegary odor. It has a molecular weight of 180.16 g/mole and a molecular formula CHO.
Durlaza capsules also include the following inactive ingredients: ethylcellulose, povidone, castor oil, tartaric acid, magnesium stearate, colloidal anhydrous silica, and talc.
The capsule shell contains gelatin and titanium dioxide.
What does DURLAZA look like?
What are the available doses of DURLAZA?
DURLAZA (aspirin) Extended Release Capsules are supplied as white to off-white opaque capsules each containing 162.5 mg of aspirin.
What should I talk to my health care provider before I take DURLAZA?
How should I use DURLAZA?
DURLAZA is indicated to:
Limitation of Use
The recommended dose of DURLAZA is one capsule (162.5 mg) once daily. Take the capsules with a full glass of water at the same time each day.
Swallow DURLAZA capsules whole. Do not cut, crush or chew capsules.
Do not take DURLAZA 2 hours before or 1 hour after consuming alcohol .
What interacts with DURLAZA?
Sorry No Records found
What are the warnings of DURLAZA?
Sorry No Records found
What are the precautions of DURLAZA?
Sorry No Records found
What are the side effects of DURLAZA?
Sorry No records found
What should I look out for while using DURLAZA?
DURLAZA is contraindicated:
What might happen if I take too much DURLAZA?
Salicylate toxicity may result from acute ingestion (overdose) or chronic intoxication. The early signs of salicylic overdose (salicylism), including tinnitus (ringing in the ears), occur at plasma concentrations approaching 200 mcg/mL. Plasma concentrations of aspirin above 300 mcg/mL are clearly toxic. Severe toxic effects are associated with levels above 400 mcg/mL A single lethal dose of aspirin in adults is not known with certainty but death may be expected at 30 g. For real or suspected overdose, contact a Poison Control Center immediately.
Signs and Symptoms: In acute overdose, severe acid-base and electrolyte disturbances may occur and are complicated by hyperthermia and dehydration. Respiratory alkalosis occurs early while hyperventilation is present, but is quickly followed by metabolic acidosis.
Treatment: Treatment consists primarily of supporting vital functions, increasing salicylate elimination, and correcting the acid-base disturbance. Gastric emptying or lavage is recommended as soon as possible after ingestion, even if the patient has vomited spontaneously. After lavage or emesis, administer activated charcoal, as a slurry, if less than 3 hours have passed since ingestion.
Severity of aspirin intoxication is determined by measuring the blood salicylate level. Monitor acid-base status with serial blood gas and serum pH measurements. Maintain fluid and electrolyte balance.
In severe cases, hyperthermia and hypovolemia are the major immediate threats to life. Replace fluid intravenously and correct acidosis. Monitor plasma electrolytes and pH to promote alkaline diuresis of salicylate if renal function is normal. Glucose may be required to control hypoglycemia.
Hemodialysis and peritoneal dialysis can reduce the body aspirin content. In patients with renal insufficiency or in cases of life-threatening intoxication, dialysis is usually required. Exchange transfusion may be indicated in infants and young children.
How should I store and handle DURLAZA?
As with other potentially toxic anticancer agents, care should be exercised in the handling and preparation of infusion solutions prepared from oxaliplatin. The use of gloves is recommended. If a solution of oxaliplatin contacts the skin, wash the skin immediately and thoroughly with soap and water. If oxaliplatin contacts the mucous membranes, flush thoroughly with water.Procedures for the handling and disposal of anticancer drugs should be considered. Several guidelines on the subject have been published . There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.As with other potentially toxic anticancer agents, care should be exercised in the handling and preparation of infusion solutions prepared from oxaliplatin. The use of gloves is recommended. If a solution of oxaliplatin contacts the skin, wash the skin immediately and thoroughly with soap and water. If oxaliplatin contacts the mucous membranes, flush thoroughly with water.Procedures for the handling and disposal of anticancer drugs should be considered. Several guidelines on the subject have been published . There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.DURLAZA Capsules, 162.5 mg, are supplied as follows:Size 2 white to off-white opaque capsules imprinted with the name DurlazaBottles of 30 capsules NDC 58487-001-01Bottles of 90 capsules NDC 58487-001-02Special Precautions for Storage: Store at 25 °C (77 °F); excursions permitted to 15 - 30°C (59 -86°F) [see USP Controlled Room Temperature].DURLAZA Capsules, 162.5 mg, are supplied as follows:Size 2 white to off-white opaque capsules imprinted with the name DurlazaBottles of 30 capsules NDC 58487-001-01Bottles of 90 capsules NDC 58487-001-02Special Precautions for Storage: Store at 25 °C (77 °F); excursions permitted to 15 - 30°C (59 -86°F) [see USP Controlled Room Temperature].DURLAZA Capsules, 162.5 mg, are supplied as follows:Size 2 white to off-white opaque capsules imprinted with the name DurlazaBottles of 30 capsules NDC 58487-001-01Bottles of 90 capsules NDC 58487-001-02Special Precautions for Storage: Store at 25 °C (77 °F); excursions permitted to 15 - 30°C (59 -86°F) [see USP Controlled Room Temperature].DURLAZA Capsules, 162.5 mg, are supplied as follows:Size 2 white to off-white opaque capsules imprinted with the name DurlazaBottles of 30 capsules NDC 58487-001-01Bottles of 90 capsules NDC 58487-001-02Special Precautions for Storage: Store at 25 °C (77 °F); excursions permitted to 15 - 30°C (59 -86°F) [see USP Controlled Room Temperature].DURLAZA Capsules, 162.5 mg, are supplied as follows:Size 2 white to off-white opaque capsules imprinted with the name DurlazaBottles of 30 capsules NDC 58487-001-01Bottles of 90 capsules NDC 58487-001-02Special Precautions for Storage: Store at 25 °C (77 °F); excursions permitted to 15 - 30°C (59 -86°F) [see USP Controlled Room Temperature].
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Aspirin [acetylsalicylic acid (ASA)] inhibits prostaglandin synthesis resulting in inhibition of platelet aggregation for their lifespan of about 7-10 days. The acetyl group of aspirin binds with a serine residue of cyclooxygenase-1 (COX-1)resulting in irreversible inactivation of the enzyme. Inhibition of COX-1 prevents conversion of arachidonic acid to thromboxane A (TXA), which is a potent agonist of platelet aggregation.
Non-Clinical Toxicology
DURLAZA is contraindicated:Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.
Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.
The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.
Concurrent use of tetracycline may render oral contraceptives less effective.
DURLAZA increases the risk of bleeding. Risk factors for bleeding include the use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs)
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
518Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).